欢迎来到CSNpharm！产品仅用于科研！

400-920-2911 sales@csnpharm.cn

NEW 新产品
0

FLT3

FLT3

货号 产品名 CAS号 信息
CSN15695 UNC2025 1429881-91-3 UNC2025 is an inhibitor of Mer and Flt3 with IC50 of 0.8 nM and 0.74 nM, respectively.
CSN19156 UNC2025 hydrochloride 2070015-17-5 UNC2025 HCl is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3.
CSN12405 Fedratinib 936091-26-8 TG 101348 is an inhibitor of JAK2 with an IC₅₀ of 6 nM and also inhibits related kinases FLT3, RET, and JAK3 with less potent activity, having IC₅₀ values of 25, 17 and 169 nM, respectively.
CSN13941 TCS 359 301305-73-7 TCS 359, a 2-acylaminothiophene-3-carboxamide, is a potent inhibitor of FLT3 with IC50 of 42 nM.
CSN12033 Tandutinib 387867-13-2 Tandutinib is an antagonist of FLT3 with IC50 of 0.22 μM and can also inhibit PDGFR and c-Kit thereby inhibiting cellular proliferation and inducing apoptosis.
CSN24785 TAK-659 1312691-33-0 TAK-659 is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC50 of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. TAK-659 induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL)[1][2][3][4].
CSN20533 (Z)-SU5614 1055412-47-9 SU-5614 is an inhibitor of FLT3. In Ba/F3 and AML cell lines expressing a constitutively activated FLT3, SU-5614 exhibits significant cell growth inhibition and cell cycle arrest.
CSN13100 Quizartinib 950769-58-1 Quizartinib is a second-generation FLT3 inhibitor for Flt3 (ITD/WT) with IC50 of 1.1 nM/4.2 nM, being 10-fold selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R.
CSN17212 Pexidartinib 1029044-16-3 Pexidartinib is a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with IC50s of 20, 10, and 160 nM in vitro, respectively.
CSN17304 KW-2449 1000669-72-6 KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 with IC50 of 6.6 nM, modestly potent to FGFR1, Bcr-Abl and Aurora A, and showing little effect on PDGFRβ, IGF-1R, EGFR.
CSN13926 Gilteritinib 1254053-43-4 Gilteritinib is a potent FLT3/AXL inhibitor with IC50 of 0.29 nM/< 1 nM respectively and shows potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations.
CSN21227 Gilteritinib hemifumarate 1254053-84-3 Gilteritinib hemifumarate is an inhibitor of FLT3 and AXL with IC50 of 0.29 nM and 0.73 nM, respectively.
CSN13783 Denfivontinib 1457983-28-6 G-749 is a FLT3 inhibitor that showed potent and sustained inhibition of the FLT3 wild type and mutants with IC50s of 0.4/0.6/3.5/7.5 nM for Wt Flt3/D835Y/MV4-11/Molm-14 respectively.
CSN26459 FLT3-IN-6 2377141-31-4 FLT3-IN-6 is a potent and selective inhibitor of FLT3-ITD (FLT3 mutation) with an IC50 of 1.336 nM[1].
CSN16867 FLT3-IN-2 923562-23-6 FLT3-IN-2 is a FLT3 inhibitor with IC50 of < 1 μM.
CSN21240 (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide succinate(1:x) 1702864-11-6 FLT3-IN-1 Succinate is a potent FLT3 inhibitor extracted from patent WO2015056683A1, compound example A.
CSN21235 FF-10101 1472797-69-5 FLT3-IN-1 is a potent FLT3 inhibitor extracted from patent WO2015056683A1, compound example A
CSN16265 SKLB4771 1370256-78-2 FLT3-IN-1 is a potent and selective Flt3 inhibitor with IC50 of 10 nM and against FLT3-ITD-expressing MV4-11 cells with IC50 of 6 nM.
CSN27527 Fedratinib hydrochloride hydrate 1374744-69-0 Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research.
CSN20591 Famitinib 1044040-56-3 Famitinib, a structural analogue of sunitinib, is a multi-targeted receptor tyrosine kinase inhibitor which is potential for treatment of renal cell carcinoma, gastrointestinal stromal tumours, pancreatic cancer, and nasopharyngeal carcinoma.
CSN32928 Famitinib malate 1256377-67-9 Famitinib is a novel multi-targeted receptor tyrosine kinase inhibitor under development for cancer treatment.
CSN18598 ENMD-2076 934353-76-1 ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFRα.
CSN24802 BPR1K871   2443767-35-7 DBPR114 is a potent multi-kinase inhibitor with potent activities against more than 57 oncogenic kinases, including Aurora-A, FLT3, CSF1R, MET, etc. DBPR114 exhibited favorable PK profiles: a long half-life (t1/2 = 23.5 h), moderate clearance and high volume of distribution. Also DBPR114 can effectively inhibit the growth of human acute myeloid leukemia MOLM-13 and MV4-11, MIA PaCa-2, Hep3B, MKN45, Colo205, and NTUB1 solid tumor xenografts in vivo without causing significant body weight loss.
CSN16269 CTX-0294885 1439934-41-4 CTX-0294885 is a bisanilino pyrimidine and exhibits inhibitory activity against a broad range of kinases in vitro, further developed into a Sepharose-supported kinase capture reagent. CTX-0294885 is a broad spectrum kinase inhibitor that inhibited FAK, FLT3, JAK2, JAK3, Src, Aurora kinase A, and VEGF receptor 3 (IC50s = 4, 1, 3, 28, 2, 18, and 3 nM, respectively) in an initial screen.
CSN18820 Crotonoside 1818-71-9 Crotonoside is a naturally occurring active isomer of guanosine found in the seeds of Croton tiglium, which could reduce the blood pressure in rabbits and cats. Crotonoside inhibits FLT3 and HDAC3/6, exhibits selective inhibition in acute myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the treatment of AML.
CSN22754 Chmfl-flt3-122 1839150-56-9 CHMFL-FLT3-122 is a potent and selective FLT3 inhibitor with IC50 of 40 nM.
CSN27200 CCT241736 1402709-93-6 CCT241736 is a dual FLT3/Aurora kinase A/B inhibitor with IC50 values of 0.035μM, 0.015μM and 0.1μM, respectively.
CSN15710 Cabozantinib 849217-68-1 Cabozantinib is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively.
CSN16257 BPR1J-097 1327167-19-0 BPR1J-097 is a small molecule FLT-3 inhibitor (IC50=11±7 nM) with promising in vivo anti-tumour activities, inhibiting FLT-3 D835Y with an IC50 of 3 nM.
CSN25237 ATH686 853299-52-2 ATH686 is the second-generation FLT3 inhibitor.
CSN18365 AST 487 630124-46-8 AST-487 is a RET kinase inhibitor with IC50 of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits Flt-3 with IC50 of 520 nM. AST487 also inhibits RET,KDR,c-KIT,and c-ABL kinase with IC50 values below 1 μM.
CSN22654 5'-Fluoroindirubinoxime 861214-33-7 5'-Fluoroindirubinoxime is an inhibitor of FMS-like receptor tyrosine kinase-3 (FLT3) with IC50 of 15 nM.
CSN64929 ENMD-2076 Tartrate 1453868-32-0
CSN67441 OTS447 1356943-67-3
CSN51530 9-Isopropyl-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-(pyridin-3-yl)-9H-purine-2,8-diamine 1350544-93-2
<< PREV 1 2 NEXT >>
dandb BBB norton fedex dhl ups 顺丰

csnpharm版权所有2023，产品仅用于科研！

联系
我们